Plain-English translation of NCT04386967 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial tested OH2, a specially engineered virus treatment that was designed to attack cancer cells while triggering the body's immune system to fight tumors more effectively. Researchers studied whether OH2 worked better on its own or when combined with , an existing immunotherapy drug. The trial included patients with advanced melanoma and other solid tumors that had stopped responding to conventional treatments.
Many patients with advanced cancers run out of effective treatment options when standard chemotherapy and radiation fail. This medication was designed to use a modified virus to directly kill cancer cells and wake up the immune system to recognize and destroy remaining cancer, offering hope to patients with limited alternatives.
Participants received injections of the modified virus medication directly into their tumor, either as a single treatment or combined with injections. The trial involved dose-escalation, meaning different groups received different amounts to find the safest and most effective dose. Participants underwent regular medical visits, blood tests, and imaging scans to monitor how their tumors responded and to watch for any side effects from the treatment.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Enrollment target
~44 participants
Started
November 2018
Primary completion
June 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.